Compare Transocean Ltd (RIG) vs Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) (TAK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Transocean Ltd vs Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) — how do they compare? Transocean Ltd trades at $5.55 (market cap $6.19B), while Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) trades at $18.71 (market cap $58.74B). The key difference: Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) is far larger — about 9.5× Transocean Ltd's market cap, and Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) pays a 3.33% dividend while Transocean Ltd pays none. Which is the better fit depends on your goals — on Pluang, investors hold Transocean Ltd for 18 Days and Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) for 1 Days on average.
| RIG | TAK | |
|---|---|---|
Market Cap | $6.19B | $58.74B |
Volume | 30,564,415 | 3,110,994 |
Sector | Energy | Health |
52-Week High | $7.58 | $19.05 |
52-Week Low | $3.08 | $13.23 |
Typical Hold Time | 18 Days | 1 Days |
Enterprise Value | $10.80B | $86.65B |
Dividend Yield | — | 3.33% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Transocean (RIG) trades at $5.55, up 2.97% on the day, with a bullish technical signal driven by oscillators. The company reported a Q2 2026 EPS beat but remains unprofitable with a net income margin of -40.24%. Recent news highlights progress on the $5.8 billion Valaris acquisition and new contract awards, supporting cash flow growth. The stock shows mixed analyst sentiment with a 39.06% buy rating.
The outlook is speculative, hinging on successful deleveraging and offshore cycle strength. Investment opportunity lies in cash flow improvement and backlog execution, but risks include high debt, execution challenges from the Valaris deal, and persistent negative profitability. The stock presents a high-risk, event-driven play for investors betting on an offshore drilling recovery.
No Aura AI signal available yet.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Transocean Ltd
Transocean Ltd. is a leading international provider of offshore contract drilling services for oil and gas wells. The company operates one of the world's most versatile fleets of mobile offshore drilling units, including ultra-deepwater drillships and harsh environment semi-submersibles. RIG's services are essential to energy exploration and production companies seeking to access deepwater and challenging reserves globally.
Read more on RIG →About Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock)
Takeda is a Japanese pharmaceutical company developing medicines across areas including gastrointestinal disease, rare diseases, neuroscience, oncology, and plasma-derived therapies.
Read more on TAK →
